GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GemPharmatech Co Ltd (SHSE:688046) » Definitions » Ending Cash Position

GemPharmatech Co (SHSE:688046) Ending Cash Position : ¥561.6 Mil (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is GemPharmatech Co Ending Cash Position?

GemPharmatech Co's Ending Cash Position for the quarter that ended in Mar. 2024 was ¥561.6 Mil.

GemPharmatech Co's quarterly Ending Cash Position declined from Sep. 2023 (¥661.7 Mil) to Dec. 2023 (¥560.0 Mil) but then increased from Dec. 2023 (¥560.0 Mil) to Mar. 2024 (¥561.6 Mil).

GemPharmatech Co's annual Ending Cash Position increased from Dec. 2021 (¥293.5 Mil) to Dec. 2022 (¥421.6 Mil) and increased from Dec. 2022 (¥421.6 Mil) to Dec. 2023 (¥560.0 Mil).

GemPharmatech Co Ending Cash Position Historical Data

The historical data trend for GemPharmatech Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GemPharmatech Co Ending Cash Position Chart

GemPharmatech Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Ending Cash Position
Get a 7-Day Free Trial 221.90 524.17 293.52 421.59 559.99

GemPharmatech Co Quarterly Data
Dec18 Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 447.07 589.74 661.68 559.99 561.60

GemPharmatech Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

GemPharmatech Co's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=421.592+138.401
=560.0

GemPharmatech Co's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=559.993+1.605
=561.6

GemPharmatech Co Ending Cash Position Related Terms

Thank you for viewing the detailed overview of GemPharmatech Co's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

GemPharmatech Co (SHSE:688046) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GemPharmatech Co Ltd (SHSE:688046) » Definitions » Ending Cash Position
Comparable Companies
SHSE:603566 SZSE:301333 SHSE:600200 SZSE:300181 SHSE:603896 SHSE:603718 SHSE:688513 SHSE:603439 SHSE:688197 SZSE:301080 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
No. 12, Xuefu Road, Jiangbei New District, Jiangsu Province, Nanjing, CHN, 210032
Website
https://www.gempharmatech.us
GemPharmatech Co Ltd is a provider of?genetically engineered mouse?models?and services to global preclinical research and development communities. It specializes in developing animal models using cutting edge gene-editing technologies with a large collection of?cKO/KO (conditional knockout/knockout) mice, humanized mice, immunodeficient mice, and germ-free mice.

GemPharmatech Co (SHSE:688046) Headlines

No Headlines